Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count

Asian Pacific Journal of Allergy and Immunology

Volumn 25, Issue 2-3, 2007, Pages 147-154

  Tansuphaswadikul, Somsit ^a   Aung, Saw Eindani ^b   Phonrat, Benjaluck ^b   Kaewkungwal, Jaranit ^b   Pitisuttithum, Punnee ^b   Maek a nantawat, Wirach ^b  

^a Bamrasnaradura Infectious Disease Institute   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; GPO VIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE; SULFAMETHOXAZOLE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ANAMNESIS; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG HYPERSENSITIVITY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SKIN TOXICITY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CAUSALITY; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FEMALE; HIV; HIV INFECTIONS; HUMANS; LIVER; MALE; NEVIRAPINE; RETROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 36048951337     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N engl J Med 1798; 338: 853-60.
2. Sabbatani S, Manfredi R, Biagetti C, Chiodo F. Antiretroviral therapy in the real world Population-based pharmacoeconomic analysis of administration of anti-HIV regimens to 990 patients. Clin Drug Invest 2005; 25: 527-35.
3. Autar RS, Sankote J, Mahanontharit A, Ubolyam S, Giel D, Cooper D, et al. Results from pilot quality control program of generic antiretrovirals: content and dissolution analysis of generic nevirapine (HIV-NAT026). 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 2005 [Abstract No. 1412].
4. Boehringer Ingelheim Pharmaceuticals Inc. Nevirapine (Viramines) Product Monograph. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc., 2004.
5. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20: 1071-92.
6. National Department of Health. National antiretroviral treatment guidelines. 1st ed. 2004. http://www.doh.gov.za/docs/factsheets/ guidelines/artguidelines04/sec4.pdf, accessed on 24 February 2007.
7. Montaner JS, Cahn P, Zala C, Casssetti L, Losso M, Hall DB, et al. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr 2003; 33: 41-6.
8. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19: 185-92.
9. Barreiro P, Soriano V, Casas E, Estrada V, Tellez MJ, Hoetelmans R, et al. Prevention of nevirapine associated ex-anthema using slow dose escalation and/or corticosteroids. AIDS 2000; 14: 2153-7.
10. Cooper CL, van Heeswijk RPG. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med 2007; 8: 1-7.
11. Martinez E, Blanco JL, Amaiz AJ, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing anti-retroviral therapy. AIDS 2001; 15: 1261-8.
12. Stem JO, Robinson PA, Love J, Janes S, Imperiale MS, Mayers DL. A comprehensive safety analysis of nevirapine in different population of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34(Suppl): 21-33.
13. The Department of Health and Human Services (DHHS) Panel on Antiretroviral, 2006. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - May 4, 2006.
14. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immun Defic Syndr 2004; 35: 492-502.
15. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed dose combination of stavudine, lamivudine and nevirapine (GPO-Vir) for the treatment of advanced HIV infected patients: a 24 week study. J Med Assoc Thai 2004; 87: 760-7.
16. Barbaro G, Di Lorenzo G, Soldini M, Parrotto S, Bellomo G, Belloni G, et al. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol 1996; 91: 2569-73.
17. Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40: 588-93.
18. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Thomas DL. Hepatotoxicity associated with nevirapine- or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-9.
19. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003; 23: 173-82.
20. Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y. National adult antiretroviral therapy guidelines in resource- Iimited countries: concordance with 2003 WHO guidelines? AIDS 2006; 20: 1497-1502.
21. Bonjoch A, Paredes R, Domingo P, Cervantes M, Pedrol E, Ribera E, et al. Long-term safety and efficacy of nevirapine based approaches in HIV type 1 -infected patients. AIDS Res Hum Retroviruses 2006; 22: 321-9.
22. Ribera E, Rodriguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, et al. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naïve HIV-infected patients. Antivir Ther 2005; 10: 605-14.
23. Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW. Stavudine, larnivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev 2006; 2: CD004535.
24. Manosuthi W, Churnpathat N, Chaovavanich A, Sungkanuparph S. Safety and tolerability of nevirapine based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. BMC Infectious Diseases 2005; 5: 67.
25. Milinkovic A, Martinez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther 2004; 2: 367-73.
26. Manfredi R, Calza L. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl. AIDS 2006; 20: 2233-6.
27. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet 2004; 364: 69-82.
28. de Maat MM, Huitema AD, Mulder JW et al. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54: 378-85.
29. Derisi M, Ballard C, Abulhson K, Colwell B, Barber E, Mathews WC. Sulfa-associated rash and race are risk factors for non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated rash. Retroviral Conference. San Francisco, CA, February 2000 [Abstract No.61].
30. Bersoff-Matcha SJ, Miller WC, Aberg JA, Horst C, Hamrick HJ Jr., Powderly WG, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-9.
31. Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001; 1: 311-6.
32. Vilar FJ, Naisbitt DJ, Park BK, Pirmohamed M. Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system. J HIV Ther 2003; 8: 42-7.
33. Manfredi R. HIV infection, antiretroviral therapy, and hepatic function: emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management. AIDS 2003; 17: 2253-6.
34. Verucchi G, Calza L, Manfredi R, Chiodo F. Incidence of liver toxicity in HIV-infected patients receiving isolated dual nucleoside analogue antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33: 546-8.